The FDA announced Breakthrough Therapy Designation (BTD) for acalabrutinib (Calquence) as a single agent to treat chronic lymphocytic leukemia (CLL)
PRIME Archived Webinars Now Online!
PRIME in partnership with the CLL Society and the Leukemia & Lymphoma Society (LLS) offers this endured webcast led by Dr. John Byrd and Dr. Brian Koffman as they address concerns of patients and providers on how to best manage toxicities associated with novel CLL/SLL and FL therapies. Hone your clinical skills with real-world patient cases and listen to effective strategies aimed at improving care coordination, managing and mitigating toxicities, and enhancing transitions of care.
Expert hematologists/oncologists and a passionate patient advocate discuss ways to improve outcomes in the relapsed/refractory setting of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL). Considerations for collaborative treatment decision-making between oncology teams and their patients will be shared. This archived webinar, conducted in partnership with the Leukemia & Lymphoma Society (LLS) and The CLL Society, illustrates real-world patient survey data collected by PRIME to support patient-centered care approaches.
Related posts
